ArticleDermatology and therapy2026
Real-World Ritlecitinib Treatment of Severe Alopecia Areata in the United States: Patient Characteristics and Physician Satisfaction According to a Secondary Database Analysis.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dermatologists' Perspectives and Real-World Assessment of Alopecia Areata Severity, Burden, and Healthcare Resource Utilization in Adults in the United Arab Emirates.Dermatology and therapy · 2026Article
- Dermatologists' Perspectives and Real-World Assessment of Alopecia Areata Severity, Burden, and Healthcare Resource Utilization in Adults in the Kingdom of Saudi Arabia.Dermatology and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRitlecitinib, an oral, selective dual inhibitor of Janus kinase (JAK) 3 and tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases, is approved for treating severe alopecia areata (AA) in patients aged ≥ 12 years in the USA. This study describes characteristics, treatment satisfaction, and success among adults initiating ritlecitinib.
methodsA sample of US dermatologists treating adults who received ritlecitinib for severe AA were surveyed between November 2023 and June 2024. Demographics, clinical characteristics, treatment history, satisfaction, and health-related quality of life were analyzed overall, among recent initiators, and stratified by treatment duration.
resultsA total of 123 adults were included (mean age 37.1 years; 57% male; 79% white; 88% commercial insurance). Mean disease duration was 2.1 years. At ritlecitinib initiation (n = 93), mean scalp hair loss was 71% and 73% had worsening AA. The proportion of patients with hair regrowth increased with longer treatment duration, 49% among those with < 3 months of treatment (n = 18/37) to 82% with > 6 months (n = 28/34). Physicians reported many recent initiators (n = 26) felt moderate/severe embarrassment (84%), frustration (73%), and anxiety (65%) due to their AA. Among patients with available data (n = 102), ritlecitinib was the first AA treatment for 46%. Treatment goals (n = 123) included reducing hair loss (94%), improving quality-of-life (41%), and achieving long-term control (32%). Reasons for selecting ritlecitinib (n = 113) included its ability to reduce scalp hair loss (38%), cost-benefit ratio (28%), and safety profile (25%). Satisfaction with AA control was 54%, 68%, and 85% after < 3 (n = 20/37), 3-6 (n = 27/40), and > 6 months (n = 29/34), respectively, of ritlecitinib treatment.
conclusionsMany patients experienced psychological burden due to their AA around the start of treatment. Ritlecitinib was chosen for its efficacy, safety, and cost-effectiveness. Hair regrowth, disease stability, and treatment satisfaction increased with longer ritlecitinib treatment duration suggesting sustained treatment is important for achieving treatment goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.